Category - Developments

Developments

Kane Biotech, Dechra Veterinary expand license and distribution agreement to include South America

Kane Biotech (TSXV:KNE) and Dechra Veterinary Products, a unit of Dechra Pharmaceuticals (LSE:DPH), expanded their 10-year exclusive license and distribution agreement to include South America. The agreement was...

October 16, 2019

Developments

Immunic completes enrollment for Phase 2 MS trial

Immunic (NASDAQ:IMUX) completed enrollment for its Phase 2 trial assessing IMU-838 for the treatment of relapsing-remitting multiple sclerosis (RRMS). IMU-838 is a selective immune modulator that blocks the enzyme...

October 11, 2019

Developments

Frequency Therapeutics gets FDA fast track designation for FX-322; begins Phase 2a study dosing

In addition to receiving FDA fast track designation for FX-322, Frequency Therapeutics (NASDAQ:FREQ) initiated dosing in a Phase 2a clinical study of the drug candidate for the treatment of sensorineural hearing loss...

October 11, 2019

Developments

BrainStorm completes enrollment of Phase 3 ALS trial

BrainStorm Cell Therapeutics (NASDAQ:BCLI) completed enrollment of its 200-patient Phase 3 trial evaluating NurOwn for the treatment of amyotrophic lateral sclerosis (ALS). The NurOwn process involves isolating...

October 11, 2019

Developments

Geron doses first patient in Phase 3 myelodysplastic syndrome trial

Geron (NASDAQ:GERN) dosed the first patient in its Phase 3 clinical trial evaluating imetelstat, a telomerase inhibitor, in lower risk myelodysplastic syndromes (MDSs). MDSs occur when bone marrow cells do not mature...

October 11, 2019

Developments

Profound Medical implements share consolidation for proposed NASDAQ listing

Profound Medical (TSX:PRN; OTCQX:PRFMF) implemented a one-for-10 consolidation of its shares outstanding to qualify for a potential listing on The NASDAQ Stock Market. Shareholders approved the consolidation at the...

October 11, 2019

Developments

Mereo navicixizumab gets FDA fast track designation for ovarian cancer

Mereo BioPharma’s (NASDAQ:MREO) navicixizumab received FDA fast track designation for the treatment of high grade ovarian, primary peritoneal or fallopian tube cancer in patients who have received at least three prior...

October 8, 2019

Developments

AVROBIO doses first patient in Phase 1/2 gene therapy trial for cystinosis

AVROBIO (NASDAQ:AVRO) dosed the first patient in its Phase 1/2 clinical trial of AVR-RD-04 gene therapy for the treatment of cystinosis. Caused by a mutation in the cystinosin gene, cystinosis is a lysosomal storage...

October 8, 2019

Developments

FDA approves Pfenex osteoporosis drug

The FDA approved Pfenex’s (NASDAQ:PFNX) PF708 for the treatment of osteoporosis in patients at high risk of fracture. “The FDA’s approval of PF708 marks a major milestone in Pfenex’s history as our first approved...

October 8, 2019

Developments

Journals publish mechanism of action data for BeyondSpring’s Plinabulin

Two peer-reviewed scientific journals, Chem and Cell Reports, published new data that sheds light on the mechanism of action of BeyondSpring’s (NASDAQ:BYSI) lead Phase 3 asset, Plinabulin, which is being developed in...

October 8, 2019

Category - Developments

Subscribe